Company

Bank

Analyst

Coverage

Opinion

Wk chg

3/8 cls

Dendreon Corp. (NASDAQ:DNDN)

ISI Group

Mark Schoenebaum

Downgrade

Hold (from buy)

3%

$5.91

Schoenebaum downgraded after Dendreon CFO Gregory Schiffman commented that 1Q13 consensus revenue estimate of about $80.6M was high. "We think that sales maybe meaningfully below Q4," Schiffman said. The company reported pro forma 4Q12 revenues of $81.6M in late February. Schoenebaum said he has limited visibility on sales of prostate cancer product Provenge sipuleucel-T beyond 2Q13, and cannot "in good conscience" continue to carry a Buy rating.

Dyax Corp. (NASDAQ:DYAX)

Jefferies

Biren Amin

New

Buy

25%

$4.15